BC Innovations | Nov 15, 2019
Product Development

Lupus makes leaps with three good pieces of news

The lupus community gets its first break in a long while with three products showing efficacy in late-stage trials for systemic lupus erythematosis. That is welcome news in a disease that saw seven compounds fail...
BC Extra | Nov 13, 2019
Clinical News

Three late-stage wins shift the clinical landscape in SLE

A trio of companies reported positive data from late-stage systemic lupus erythematosis trials, raising hopes that new treatments are on the horizon for an indication that has seen only one new therapy approved in the...
BC Innovations | May 15, 2019
Distillery Therapeutics

Inhibiting S1PR1 for neuropathic pain

DISEASE CATEGORY: Neurology INDICATION: Pain Rat and mouse studies suggest S1PR1 inhibitors or modulators could help treat neuropathic pain. In a rat model of neuropathic pain, astrocyte-specific knockout of S1PR1 in the CNS or intrathecal...
BC Extra | Jun 16, 2017
Financial News

Actelion spinout Idorsia rises in first trading day

Idorsia Ltd. (SIX:IDIA) gained CHF3.65 (37%) to CHF13.65 in its first day of trading on Friday. The closing price valued the company at CHF1.5 billion ($1.5 billion). Idorsia was spun out of Actelion Ltd. (SIX:ATLN),...
BC Extra | Jun 9, 2017
Financial News

Actelion spinout Idorsia to list next week

On June 16, shares of Idorsia Ltd. (Allschwil, Switzerland) are to begin trading on the SIX Swiss Exchange. Idorsia will house the drug discovery and early clinical pipeline businesses of Actelion Ltd. (SIX:ATLN), which Johnson...
BC Week In Review | May 26, 2017
Clinical News

Actelion reports Phase II data for cenerimod in SLE

Actelion Ltd. (SIX:ATLN) reported data from a double-blind, placebo-controlled Phase II trial in 67 patients with systemic lupus erythematosus (SLE) showing that cenerimod dose-dependently reduced lymphocyte count. Cenerimod was well tolerated. Patients received placebo or...
BC Extra | May 22, 2017
Clinical News

Actelion reports hypertension data amid Idorsia spinout

In a pipeline update outlining candidates it plans to spin out into newco Idorsia Ltd. , Actelion Ltd. (SIX:ATLN) said ACT-132577 led to "statistically significant dose-dependent" reductions in both diastolic and systolic blood pressure in a...
BioCentury | Feb 4, 2017
Strategy

Actelion, take two

After surviving takeover attempts, an investor mutiny and a make-or-break gamble on Opsumit macitentan, Actelion Ltd. co-founder and CEO Jean-Paul Clozel finally took a deal management couldn’t refuse. Johnson & Johnson ’s proposed $30 billion...
Items per page:
1 - 8 of 8